Similar late outcomes with TAVR and SAVR in high-risk patients

Reuters Health - 09/10/2020 - Patients with severe aortic stenosis who undergo transcatheter aortic-valve replacement (TAVR) initially do better than their counterparts receiving surgical aortic-valve replacement (SAVR), but there is little difference in longer-term health status between the two groups. As Dr. Suzanne V. Arnold told Reuters Health by email, "we found that despite differences in complications between SAVR and TAVR, patients who survive appear to maintain a reasonable quality of life through five years." Dr. Arnold of Saint Luke's Mid America Heart Institute, in Kansas City, Missouri, and colleagues conducted a pre-specified analysis of data from the CoreValve US High Risk Pivotal Trial, in which patients at high surgical risk with severe aortic stenosis were randomized to either self-expanding TAVR or SAVR. Baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) health status was available for 713 patients. Their mean age was 83 years and the...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 October, 202022 October, 2020